Personalized mRNA Cancer Vaccine Cuts Melanoma Recurrence by 49% in 5-Year Trial

Five years after receiving an experimental, custom-built mRNA cancer vaccine, patients with high-risk melanoma are showing unprecedented rates of survival and disease-free progression. Detailed results from the Phase 2b KEYNOTE-942 trial, presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, reveal that combining Moderna's personalized vaccine with Merck's immunotherapy drug Keytruda reduces the risk of cancer recurrence or death by 49% compared to Keytruda alone.[1]

The findings represent a critical milestone in oncology: the first long-term proof that mRNA technology—the same platform that ended the acute phase of the COVID-19 pandemic—can be successfully weaponized against solid tumors. By maintaining its efficacy over a half-decade, the combination therapy suggests that the immune system can be permanently reprogrammed to hunt down microscopic cancer cells that evade surgical removal.[4]

The evidence stems from a randomized, open-label trial involving 157 patients with stage III or IV melanoma who had undergone complete surgical resection. These patients face a notoriously high risk of their cancer returning and spreading to distant organs. In the study, two-thirds of the cohort received the combination therapy, while the remaining third received only Keytruda, the current standard of care.[3]

The five-year data, simultaneously published in the Journal of Clinical Oncology, provides a stark contrast in outcomes. Overall survival in the combination arm reached 92.2%, compared to 71.3% for patients receiving only the immunotherapy. Furthermore, the dual regimen reduced the risk of distant metastasis—the spread of cancer to other organs, which is often fatal—by 59%.[2][3]

"The benefits we have seen with respect to improved relapse-free survival have persisted over time," noted researchers at the ASCO presentation, emphasizing that the 49% risk reduction reported at the five-year mark remains identical to the results seen at the three-year interim analysis. This stability is what oncologists refer to as a "maintenance of effect," indicating durable immune surveillance rather than a temporary delay in recurrence.[2][4]

The mechanism driving these results relies on a highly personalized approach to medicine. The vaccine, officially named intismeran autogene (and formerly known as mRNA-4157 or V940), is not pulled from a pharmacy shelf. Instead, it is custom-manufactured for each individual patient over a period of six to eight weeks.[1]

The process begins with a biopsy of the patient's surgically removed tumor. Scientists sequence the tumor's DNA to identify its unique mutational signature, selecting up to 34 specific "neoantigens"—abnormal proteins found only on the surface of the cancer cells. These genetic instructions are encoded into a synthetic mRNA strand and injected into the patient.[1][3]

Once administered, the mRNA instructs the patient's own cells to produce these neoantigens, effectively training the immune system's T-cells to recognize and attack any remaining melanoma cells. However, tumors often deploy chemical signals to hide from the immune system. This is where Keytruda (pembrolizumab), a PD-1 inhibitor, plays its crucial role: it strips away the tumor's chemical disguise, allowing the newly trained T-cells to execute their precision attack.[4]

A primary concern with combining powerful immunotherapies is the potential for compounding toxicities. However, the five-year safety data indicates that adding the mRNA vaccine does not significantly increase severe side effects. Immune-related adverse events occurred in 45.2% of patients receiving the combination, compared to 44% of those receiving Keytruda alone.[3]

The most common side effects attributed to the vaccine were relatively mild and transient, mirroring those seen with mRNA viral vaccines: fatigue (60.6%), injection site pain (56.7%), and chills (49%). No grade 4 or 5 (life-threatening or fatal) adverse events were reported in connection with the combination regimen.[1][2]

Despite the overwhelmingly positive data, transparent uncertainty remains regarding the therapy's definitive clinical standing. The KEYNOTE-942 study is a Phase 2b trial, meaning it was designed to demonstrate proof-of-concept and establish dosing, rather than to serve as the final word on efficacy. The sample size of 157 patients is relatively small for a definitive oncology protocol.[3][4]

Furthermore, while the overall survival figures (92.2% vs 71.3%) are highly encouraging, the trial was not statistically powered to use overall survival as its primary endpoint. The primary metric was recurrence-free survival. Consequently, regulatory agencies like the FDA will require data from larger cohorts before granting full approval for the regimen to replace the current standard of care.[4]

That definitive evidence is currently being gathered. A global Phase 3 trial (INTerpath-001) evaluating the combination in adjuvant melanoma is fully enrolled, with interim data expected to read out in late 2026 or early 2027. If the Phase 3 data mirrors the Phase 2b results, it will likely trigger a paradigm shift in how high-risk skin cancers are treated globally.[1][4]

The implications extend far beyond melanoma. Because the mRNA platform is agnostic to the type of cancer—relying only on the genetic sequence of the individual tumor—the same plug-and-play technology is being aggressively tested against other malignancies.[1]

Merck and Moderna have already initiated Phase 3 clinical trials (INTerpath-002 and INTerpath-009) evaluating the bespoke vaccine in patients with non-small cell lung cancer (NSCLC), the leading cause of cancer death worldwide. Additional mid-stage trials are underway for renal cell carcinoma and bladder cancer, signaling a broad offensive against solid tumors.[4]

For decades, the concept of a "cancer vaccine" was marred by clinical failures and dashed hopes. The sustained five-year success of intismeran autogene provides the strongest evidence to date that by combining the rapid adaptability of mRNA with the brute force of checkpoint inhibitors, a functional cure for high-risk cancers may finally be within reach.[2][4]